ARTICLE | Emerging Company Profile
Going non-viral
Why Generation Bio’s ceDNA vectors could treat diseases AAVs cannot
February 3, 2018 1:36 AM UTC
Generation Bio Co. aims to take gene therapies into pediatric and other indications where adeno-associated virus vectors have not been able to go.
The company is developing preclinical gene therapies that are encoded in eukaryotic closed-ended DNA (ceDNA) vectors, which are linear, double-stranded DNA molecules whose ends have been closed via covalent linkages...
BCIQ Company Profiles